Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 84.24 0 (0%) Market Cap: 52.81 Bil Enterprise Value: 46.88 Bil PE Ratio: 0 PB Ratio: 7.72 GF Score: 32/100

Intra-Cellular Therapies Inc to Discuss the Top-line Results of Studies 401 and 404 Call Transcript

Jul 08, 2019 / 12:00PM GMT
Operator

Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies conference call. (Operator Instructions)

I would now like to hand the call over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. You may begin.

Juan Fernando Sanchez
Intra-Cellular Therapies, Inc. - VP of Corporate Communications & IR

Thank you, operator. Good morning and thank you all for joining us on today's conference call to discuss the topline results from Study 404 and 401, our 2 studies evaluating lumateperone as monotherapy in patients with bipolar depression. Our press release announcing the results crossed the wire a short time ago and is available on our website at intracellulartherapies.com.

Joining me on the call today are Dr. Sharon Mates, Chairman and CEO; Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer; Dr. Kimberly Vanover, Senior Vice President of Early Stage Clinical Development and Translational Medicine; and Michael Halstead, Executive Vice President and General Counsel.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot